Literature DB >> 8340056

Glucose resistance contributes to diabetes mellitus in cirrhosis.

A S Petrides1, D Schulze-Berge, C Vogt, D E Matthews, G Strohmeyer.   

Abstract

Insulin resistance is a characteristic feature of glucose-intolerant and diabetic cirrhotic patients. The pathogenic factors, however, that are responsible for the development of impaired glucose tolerance in cirrhosis, remain unclear. To examine whether the ability of hyperglycemia per se to enhance glucose uptake (by means of mass-action effect) is impaired in cirrhosis, we measured (insulin-independent) whole-body glucose disposal during hyperglycemia (hyperglycemic clamp studies, +125 mg/dl, in combination with an infusion of somatostatin (500 micrograms/hr), insulin (0.1 mU/kg min) and glucagon (0.5 ng/kg min) to "clamp" hormone levels at baseline), whole-body glucose oxidation (indirect calorimetry) and glucose turnover (prime-continuous infusion of [6,6-2H2-]glucose in a clinically homogeneous group of cirrhotic patients with glucose intolerance (n = 7) or frank diabetes mellitus (n = 7) and in control individuals (n = 7). Fasting plasma glucose concentrations were normal in glucose-intolerant patients but were significantly increased in diabetic patients (158 +/- 19 vs. 87 +/- 2 mg/dl in controls; p < 0.01). Plasma glucose concentrations were clamped at 214 +/- 4 mg/dl in controls, at 212 +/- 4 mg/dl in glucose-intolerant patients and at 287 +/- 19 mg/dl in diabetic patients; plasma insulin and glucagon concentrations were maintained at baseline levels. In the basal state, total-body glucose disposal (which equals basal hepatic glucose output) was normal in glucose-intolerant patients (2.25 +/- 0.11 mg/kg min) but was increased in diabetic patients compared with controls (3.32 +/- 0.26 mg/dl vs. 2.45 +/- 0.10 mg/dl; p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8340056

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

Authors:  C Rabe; T Pilz; C Klostermann; M Berna; H H Schild; T Sauerbruch; W H Caselmann
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Effects of collateral vessel occlusion on oral glucose tolerance test in liver cirrhosis.

Authors:  N Tanabe; M Ishii; Y Sato; T Akahane; N Kobayashi; H Gama; T Iwasaki; T Toyota
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

Review 3.  Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Investig       Date:  1994-08

4.  Impaired gluconeogenesis in a porcine model of paracetamol induced acute liver failure.

Authors:  Konstantinos J Dabos; Henry R Whalen; Philip N Newsome; John A Parkinson; Neil C Henderson; Ian H Sadler; Peter C Hayes; John N Plevris
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

5.  Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension.

Authors:  Tsuyoshi Ishikawa; Shogo Shiratsuki; Takashi Matsuda; Takuya Iwamoto; Taro Takami; Koichi Uchida; Shuji Terai; Takahiro Yamasaki; Isao Sakaida
Journal:  J Gastroenterol       Date:  2013-10-05       Impact factor: 7.527

6.  Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion.

Authors:  Taira Kuroda; Masashi Hirooka; Mitsuhito Koizumi; Hironori Ochi; Yoshiko Hisano; Kenji Bando; Bunzo Matsuura; Teru Kumagi; Yoichi Hiasa
Journal:  J Gastroenterol       Date:  2014-10-05       Impact factor: 7.527

7.  Prevalence and determinants of diabetes mellitus among Iranian patients with chronic liver disease.

Authors:  Seyed M Alavian; Behzad Hajarizadeh; Fariborz Nematizadeh; Bagher Larijani
Journal:  BMC Endocr Disord       Date:  2004-11-19       Impact factor: 2.763

8.  Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease.

Authors:  Shoko Kuriyama; Yoshiyuki Miwa; Hideki Fukushima; Hironori Nakamura; Katsuhisa Toda; Makoto Shiraki; Masahito Nagaki; Mayumi Yamamoto; Eiichi Tomita; Hisataka Moriwaki
Journal:  J Clin Biochem Nutr       Date:  2007-03       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.